Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Copenhagen - Delayed Quote DKK

Bavarian Nordic A/S (BAVA.CO)

155.90
-2.55
(-1.61%)
At close: 4:59:46 PM GMT+2
Loading Chart for BAVA.CO
  • Previous Close 158.45
  • Open 161.00
  • Bid 155.90 x --
  • Ask 156.25 x --
  • Day's Range 155.75 - 161.80
  • 52 Week Range 123.30 - 300.00
  • Volume 317,691
  • Avg. Volume 274,793
  • Market Cap (intraday) 12.131B
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) 12.37
  • EPS (TTM) 12.60
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 267.67

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,605

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAVA.CO

View More

Performance Overview: BAVA.CO

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

BAVA.CO
17.67%
OMX Copenhagen 25 Index (^OMXC25)
4.90%

1-Year Return

BAVA.CO
2.47%
OMX Copenhagen 25 Index (^OMXC25)
10.49%

3-Year Return

BAVA.CO
17.31%
OMX Copenhagen 25 Index (^OMXC25)
1.80%

5-Year Return

BAVA.CO
6.31%
OMX Copenhagen 25 Index (^OMXC25)
38.96%

Compare To: BAVA.CO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAVA.CO

View More

Valuation Measures

Annual
As of 5/5/2025
  • Market Cap

    12.33B

  • Enterprise Value

    10.28B

  • Trailing P/E

    12.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.16

  • Price/Book (mrq)

    1.08

  • Enterprise Value/Revenue

    1.80

  • Enterprise Value/EBITDA

    6.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.28%

  • Return on Assets (ttm)

    4.60%

  • Return on Equity (ttm)

    9.09%

  • Revenue (ttm)

    5.72B

  • Net Income Avi to Common (ttm)

    987.98M

  • Diluted EPS (ttm)

    12.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.18B

  • Total Debt/Equity (mrq)

    1.39%

  • Levered Free Cash Flow (ttm)

    -421M

Research Analysis: BAVA.CO

View More

Company Insights: BAVA.CO

Research Reports: BAVA.CO

View More

People Also Watch